{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:36:27Z","timestamp":1795012587585,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adeno-associated viruses (AAVs) are common vectors in gene therapy but can frequently cause liver complications in patients. The mechanisms underlying AAV-related liver toxicity remain poorly understood, posing challenges for effective prevention and intervention. Here we conducted a case study of a child with spinal muscular atrophy type 1 experiencing substantial hepatitis after receiving onasemnogene abeparvovec, undertaking long- and short-read metagenomic sequencing of liver tissue. We identified manufacturing plasmid sequences with complex structures and recombination. Vector genomes had extensive disruption and concatemerization as well as numerous vector\u2013human fusion junctions. We also identified human betaherpesvirus 6B in the liver. Further work and investigation of more patients is needed to establish whether the presence of manufacturing plasmid sequences or helper viruses contribute to the formation of these complex concatemeric DNA structures in the liver, and whether these are a factor in the development of liver toxicity after AAV gene therapy.<\/jats:p>","DOI":"10.1038\/s41591-025-04073-z","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:02:47Z","timestamp":1768557767000},"page":"472-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-9469","authenticated-orcid":false,"given":"Sarah","family":"Buddle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8261-0288","authenticated-orcid":false,"given":"Li-An K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Morfopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Enrique","family":"Torres Montaguth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Scoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-1382","authenticated-orcid":false,"given":"Vanessa","family":"Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Kopec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-4674","authenticated-orcid":false,"given":"Nathaniel","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-0013","authenticated-orcid":false,"given":"Luis","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Sebire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9535-4025","authenticated-orcid":false,"given":"Hannah","family":"Macpherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmaine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Orton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-6692","authenticated-orcid":false,"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patawee","family":"Asamaphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4109-5966","authenticated-orcid":false,"given":"Georgios","family":"Ilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-483X","authenticated-orcid":false,"given":"Rajvinder","family":"Karda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Belfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ISARIC4C Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9700-0418","authenticated-orcid":false,"given":"Malcolm Gracie","family":"Semple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-793X","authenticated-orcid":false,"given":"J. Kenneth","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-101X","authenticated-orcid":false,"given":"John","family":"Counsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-4730","authenticated-orcid":false,"given":"Simon N.","family":"Waddington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1482-0889","authenticated-orcid":false,"given":"Emma C.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8246-0534","authenticated-orcid":false,"given":"Judith","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"4073_CR1","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","volume":"82","author":"HA Blair","year":"2022","unstructured":"Blair, H. A. Valoctocogene roxaparvovec: first approval. Drugs 82, 1505\u20131510 (2022).","journal-title":"Drugs"},{"key":"4073_CR2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","volume":"83","author":"Y-A Heo","year":"2023","unstructured":"Heo, Y.-A. Etranacogene dezaparvovec: first approval. Drugs 83, 347\u2013352 (2023).","journal-title":"Drugs"},{"key":"4073_CR3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon, S. Fidanacogene elaparvovec: first approval. Drugs 84, 479\u2013486 (2024).","journal-title":"Drugs"},{"key":"4073_CR4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy, S. M. Delandistrogene moxeparvovec: first approval. Drugs 83, 1323\u20131329 (2023).","journal-title":"Drugs"},{"key":"4073_CR5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy, S. M. Onasemnogene abeparvovec: first global approval. Drugs 79, 1255\u20131262 (2019).","journal-title":"Drugs"},{"key":"4073_CR6","unstructured":"Approved cellular and gene therapy products. FDA https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products (2025)."},{"key":"4073_CR7","unstructured":"Sarepta therapeutics shares safety update on ELEVIDYS. Sarepta Therapeutics https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-shares-safety-update-elevidys (2025)."},{"key":"4073_CR8","doi-asserted-by":"publisher","unstructured":"Whiteley, L. O. An overview of nonclinical and clinical liver toxicity associated with AAV gene therapy. Toxicol. Pathol. https:\/\/doi.org\/10.1177\/01926233231201408 (2023).","DOI":"10.1177\/01926233231201408"},{"key":"4073_CR9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","volume":"22","author":"PB Shieh","year":"2023","unstructured":"Shieh, P. B. et al. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial. Lancet Neurol. 22, 1125\u20131139 (2023).","journal-title":"Lancet Neurol."},{"key":"4073_CR10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/d41573-021-00164-x","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. Gene therapy community grapples with toxicity issues, as pipeline matures. Nat. Rev. Drug Discov. 20, 804\u2013805 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4073_CR11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand, D. et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J. Hepatol. 74, 560\u2013566 (2021).","journal-title":"J. Hepatol."},{"key":"4073_CR12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nmd.2024.07.004","volume":"42","author":"R Finnegan","year":"2024","unstructured":"Finnegan, R. et al. Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1. Neuromuscul. Disord. 42, 22\u201326 (2024).","journal-title":"Neuromuscul. Disord."},{"key":"4073_CR13","doi-asserted-by":"publisher","unstructured":"Gowda, V. et al. Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom. Lancet Reg. Health Eur. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100817 (2024).","DOI":"10.1016\/j.lanepe.2023.100817"},{"key":"4073_CR14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley, J. L., Jong, Y. P. de, Terhorst, C. & Herzog, R. W. Immune responses to viral gene therapy vectors. Mol. Ther. 28, 709\u2013722 (2020).","journal-title":"Mol. Ther."},{"key":"4073_CR15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","volume":"55","author":"M H\u00f6sel","year":"2012","unstructured":"H\u00f6sel, M. et al. Toll-like receptor 2\u2013mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 55, 287\u2013297 (2012).","journal-title":"Hepatology"},{"key":"4073_CR16","doi-asserted-by":"crossref","first-page":"103997","DOI":"10.1016\/j.cellimm.2019.103997","volume":"346","author":"SN Ashley","year":"2019","unstructured":"Ashley, S. N., Somanathan, S., Giles, A. R. & Wilson, J. M. TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy. Cell. Immunol. 346, 103997 (2019).","journal-title":"Cell. Immunol."},{"key":"4073_CR17","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1111\/liv.16065","volume":"44","author":"D Larrey","year":"2024","unstructured":"Larrey, D. et al. Drug-induced liver injury related to gene therapy: a new challenge to be managed. Liver Int. 44, 3121\u20133137 (2024).","journal-title":"Liver Int."},{"key":"4073_CR18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-28830-7","volume":"13","author":"K Bucher","year":"2023","unstructured":"Bucher, K. et al. Extra-viral DNA in adeno-associated viral vector preparations induces TLR9-dependent innate immune responses in human plasmacytoid dendritic cells. Sci. Rep. 13, 1890 (2023).","journal-title":"Sci. Rep."},{"key":"4073_CR19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285 (2018).","journal-title":"Hum. Gene Ther."},{"key":"4073_CR20","unstructured":"Audentes Therapeutics Inc (An Astellas Company). Comment on Docket FDA-2021-N-0651. FDA https:\/\/www.regulations.gov\/comment\/FDA-2021-N-0651-0013 (2021)."},{"key":"4073_CR21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","volume":"32","author":"J Hordeaux","year":"2024","unstructured":"Hordeaux, J. et al. High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury. Mol. Ther. 32, 952\u2013968 (2024).","journal-title":"Mol. Ther."},{"key":"4073_CR22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","volume":"14","author":"EJN Groen","year":"2018","unstructured":"Groen, E. J. N., Talbot, K. & Gillingwater, T. H. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat. Rev. Neurol. 14, 214\u2013224 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"4073_CR23","unstructured":"Zolgensma. European Medicines Agency https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma (2020)."},{"key":"4073_CR24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4073_CR25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/biomedicines2010080","volume":"2","author":"JF Wright","year":"2014","unstructured":"Wright, J. F. Product-related impurities in clinical-grade recombinant AAV vectors: characterization and risk assessment. Biomedicines 2, 80\u201397 (2014).","journal-title":"Biomedicines"},{"key":"4073_CR26","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.xphs.2021.03.024","volume":"110","author":"A Srivastava","year":"2021","unstructured":"Srivastava, A., Mallela, K. M. G., Deorkar, N. & Brophy, G. Manufacturing challenges and rational formulation development for AAV viral vectors. J. Pharm. Sci. 110, 2609\u20132624 (2021).","journal-title":"J. Pharm. Sci."},{"key":"4073_CR27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.omtm.2022.01.008","volume":"24","author":"MA Brimble","year":"2022","unstructured":"Brimble, M. A. et al. Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector preps. Mol. Ther. Methods Clin. Dev. 24, 280\u2013291 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"4073_CR28","unstructured":"Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs). FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug (2020)."},{"key":"4073_CR29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41586-023-06003-w","volume":"617","author":"S Morfopoulou","year":"2023","unstructured":"Morfopoulou, S. et al. Genomic investigations of unexplained acute hepatitis in children. Nature 617, 564\u2013573 (2023).","journal-title":"Nature"},{"key":"4073_CR30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-023-05948-2","volume":"617","author":"A Ho","year":"2023","unstructured":"Ho, A. et al. Adeno-associated virus 2 infection in children with non-A\u2013E hepatitis. Nature 617, 555\u2013563 (2023).","journal-title":"Nature"},{"key":"4073_CR31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MPG.0000000000002893","volume":"71","author":"CA Chapin","year":"2020","unstructured":"Chapin, C. A. et al. Activated CD8 T-cell hepatitis in children with indeterminate acute liver failure. J. Pediatr. Gastroenterol. Nutr. 71, 713\u2013719 (2020).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"4073_CR32","volume":"9","author":"L Atkinson","year":"2023","unstructured":"Atkinson, L. et al. Untargeted metagenomics protocol for the diagnosis of infection from CSF and tissue from sterile sites. Heliyon 9, e19854 (2023).","journal-title":"Heliyon"},{"key":"4073_CR33","doi-asserted-by":"crossref","first-page":"e1009638","DOI":"10.1371\/journal.ppat.1009638","volume":"17","author":"AF Meier","year":"2021","unstructured":"Meier, A. F. et al. Herpes simplex virus co-infection facilitates rolling circle replication of the adeno-associated virus genome. PLoS Pathog. 17, e1009638 (2021).","journal-title":"PLoS Pathog."},{"key":"4073_CR34","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","volume":"79","author":"JC Grieger","year":"2005","unstructured":"Grieger, J. C. & Samulski, R. J. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J. Virol. 79, 9933\u20139944 (2005).","journal-title":"J. Virol."},{"key":"4073_CR35","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","volume":"7","author":"J-Y Dong","year":"1996","unstructured":"Dong, J.-Y., Fan, P.-D. & Frizzell, R. A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7, 2101\u20132112 (1996).","journal-title":"Hum. Gene Ther."},{"key":"4073_CR36","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","volume":"42","author":"JA Greig","year":"2024","unstructured":"Greig, J. A. et al. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat. Biotechnol. 42, 1232\u20131242 (2024).","journal-title":"Nat. Biotechnol."},{"key":"4073_CR37","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","volume":"24","author":"I Gil-Farina","year":"2016","unstructured":"Gil-Farina, I. et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol. Ther. 24, 1100\u20131105 (2016).","journal-title":"Mol. Ther."},{"key":"4073_CR38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nm.3230","volume":"19","author":"C Kaeppel","year":"2013","unstructured":"Kaeppel, C. et al. A largely random AAV integration profile after LPLD gene therapy. Nat. Med. 19, 889\u2013891 (2013).","journal-title":"Nat. Med."},{"key":"4073_CR39","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","volume":"7","author":"M Schmidt","year":"2023","unstructured":"Schmidt, M. et al. Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B. Blood Adv. 7, 4966\u20134969 (2023).","journal-title":"Blood Adv."},{"key":"4073_CR40","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","volume":"30","author":"E Symington","year":"2024","unstructured":"Symington, E. et al. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment. Haemophilia 30, 320\u2013330 (2024).","journal-title":"Haemophilia"},{"key":"4073_CR41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1089\/hum.2009.214","volume":"21","author":"X Sun","year":"2010","unstructured":"Sun, X. et al. Molecular analysis of vector genome structures after liver transduction by conventional and self-complementary adeno-associated viral serotype vectors in murine and nonhuman primate models. Hum. Gene Ther. 21, 750\u2013761 (2010).","journal-title":"Hum. Gene Ther."},{"key":"4073_CR42","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","volume":"29","author":"DA Dalwadi","year":"2021","unstructured":"Dalwadi, D. A. et al. AAV integration in human hepatocytes. Mol. Ther. 29, 2898\u20132909 (2021).","journal-title":"Mol. Ther."},{"key":"4073_CR43","doi-asserted-by":"crossref","first-page":"1143051","DOI":"10.3389\/fped.2023.1143051","volume":"11","author":"S Warner","year":"2023","unstructured":"Warner, S., Brown, R. M., Reynolds, G. M., Stamataki, Z. & Kelly, D. A. Case report: acute liver failure in children and the human herpes virus 6-? A factor in the recent epidemic. Front Pediatr. 11, 1143051 (2023).","journal-title":"Front Pediatr."},{"key":"4073_CR44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/infdis\/jiy644","volume":"220","author":"CH Yang","year":"2019","unstructured":"Yang, C. H. et al. Evaluating for human herpesvirus 6 in the liver explants of children with liver failure of unknown etiology. J. Infect. Dis. 220, 361\u2013369 (2019).","journal-title":"J. Infect. Dis."},{"key":"4073_CR45","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1128\/jvi.71.9.6816-6822.1997","volume":"71","author":"JM Allen","year":"1997","unstructured":"Allen, J. M., Debelak, D. J., Reynolds, T. C. & Miller, A. D. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J. Virol. 71, 6816\u20136822 (1997).","journal-title":"J. Virol."},{"key":"4073_CR46","doi-asserted-by":"crossref","first-page":"9468","DOI":"10.1128\/JVI.73.11.9468-9477.1999","volume":"73","author":"J Yang","year":"1999","unstructured":"Yang, J. et al. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J. Virol. 73, 9468\u20139477 (1999).","journal-title":"J. Virol."},{"key":"4073_CR47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/JVI.79.1.364-379.2005","volume":"79","author":"Z Yan","year":"2005","unstructured":"Yan, Z., Zak, R., Zhang, Y. & Engelhardt, J. F. Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J. Virol. 79, 364\u2013379 (2005).","journal-title":"J. Virol."},{"key":"4073_CR48","volume":"20","author":"DE Wood","year":"2019","unstructured":"Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. Genome Biol. 20, 257 (2019).","journal-title":"Genome Biol."},{"key":"4073_CR49","volume":"3","author":"J Lu","year":"2017","unstructured":"Lu, J., Breitwieser, F. P., Thielen, P. & Salzberg, S. L. Bracken: estimating species abundance in metagenomics data. PeerJ Comput. Sci. 3, e104 (2017).","journal-title":"PeerJ Comput. Sci."},{"key":"4073_CR50","unstructured":"taxprofiler: Introduction. nf-core https:\/\/nf-co.re\/taxprofiler\/1.0.1.html (2023)."},{"key":"4073_CR51","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/bioinformatics\/btv317","volume":"31","author":"S Morfopoulou","year":"2015","unstructured":"Morfopoulou, S. & Plagnol, V. Bayesian mixture analysis for metagenomic community profiling. Bioinformatics 31, 2930\u20132938 (2015).","journal-title":"Bioinformatics"},{"key":"4073_CR52","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-024-01380-x","volume":"16","author":"S Buddle","year":"2024","unstructured":"Buddle, S. et al. Evaluating metagenomics and targeted approaches for diagnosis and surveillance of viruses. Genome Med. 16, 111 (2024).","journal-title":"Genome Med."},{"key":"4073_CR53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"4073_CR54","unstructured":"Kaspar, B. K., Burghes, A. & Porensky, P. Intrathecal delivery of recombinant adeno-associated virus 9. US patent US20190269798A1 (2022)."},{"key":"4073_CR55","unstructured":"Gao, G., Wilson, J. & Alvira, M. Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefore. US patent US7198951B2 (2005)."},{"key":"4073_CR56","unstructured":"Gray, J. Molecule Information, pHGTI-Adeno1 (Harvard Gene Therapy Initiative, 2004)."},{"key":"4073_CR57","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078 (2009).","journal-title":"Bioinformatics"},{"key":"4073_CR58","unstructured":"Wick, R. Porechop. GitHub https:\/\/github.com\/rrwick\/Porechop (2023)."},{"key":"4073_CR59","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1093\/bioinformatics\/bty191","volume":"34","author":"H Li","year":"2018","unstructured":"Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094\u20133100 (2018).","journal-title":"Bioinformatics"},{"key":"4073_CR60","unstructured":"Andrews, S. Redotable. GitHub https:\/\/github.com\/s-andrews\/redotable (2022)."},{"key":"4073_CR61","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"4073_CR62","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/bioinformatics\/btt593","volume":"30","author":"J Zhang","year":"2014","unstructured":"Zhang, J., Kobert, K., Flouri, T. & Stamatakis, A. PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics 30, 614\u2013620 (2014).","journal-title":"Bioinformatics"},{"key":"4073_CR63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"4073_CR64","doi-asserted-by":"crossref","first-page":"D916","DOI":"10.1093\/nar\/gkaa1087","volume":"49","author":"A Frankish","year":"2021","unstructured":"Frankish, A. et al. GENCODE 2021. Nucleic Acids Res. 49, D916\u2013D923 (2021).","journal-title":"Nucleic Acids Res."},{"key":"4073_CR65","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/bioinformatics\/btz615","volume":"36","author":"EB Stovner","year":"2020","unstructured":"Stovner, E. B. & S\u00e6trom, P. PyRanges: efficient comparison of genomic intervals in Python. Bioinformatics 36, 918\u2013919 (2020).","journal-title":"Bioinformatics"},{"key":"4073_CR66","unstructured":"Shimoyama, Y. pyCirclize. GitHub https:\/\/moshi4.github.io\/pyCirclize\/ (2025)."},{"key":"4073_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2016.08.298","volume":"84","author":"JR Brown","year":"2016","unstructured":"Brown, J. R., Shah, D. & Breuer, J. Viral gastrointestinal infections and norovirus genotypes in a paediatric UK hospital, 2014\u20132015. J. Clin. Virol. 84, 1\u20136 (2016).","journal-title":"J. Clin. Virol."},{"key":"4073_CR68","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1128\/JCM.42.11.5189-5198.2004","volume":"42","author":"F Watzinger","year":"2004","unstructured":"Watzinger, F. et al. Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J. Clin. Microbiol. 42, 5189\u20135198 (2004).","journal-title":"J. Clin. Microbiol."},{"key":"4073_CR69","doi-asserted-by":"crossref","first-page":"e97259","DOI":"10.1371\/journal.pone.0097259","volume":"9","author":"CJ Tann","year":"2014","unstructured":"Tann, C. J. et al. Prevalence of bloodstream pathogens is higher in neonatal encephalopathy cases vs. controls using a novel panel of real-time PCR assays. PLoS ONE 9, e97259 (2014).","journal-title":"PLoS ONE"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04073-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04073-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04073-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:02:50Z","timestamp":1771783370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04073-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4073"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04073-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.B. is PI of clinical trials Sponsored by Roche, Novartis, Sarepta, Pfizer, NS Pharma, Reveragen, Percheron, Biomarin and Scholar Rock and has received speaker and\/or consulting fees from Sarepta, PTC Therapeutics, Entrada Therapeutics, Pfizer, Biogen, Novartis Gene Therapies, Inc. (AveXis), and Roche, as well as grants from Sarepta, Roche and Novartis Gene Therapies. UCL has received funding from Sarepta, Roche, Pfizer, Italfarmaco, Santhera and Moderna. F.M. is the PI of the Novartis-sponsored trials in which OA was studied in the UK and is also involved in clinical trials sponsored by Biogen, Roche, Sarepta Therapeutics, Genethon, PTC therapeutics and Solid Bioscience. He has received consulting fees from Pfizer, Sarepta, Roche, Biogen, Novartis, Solid, Dyne Therapeutics, Entrada, PTC and Edgewise. M.S. is the sub-I of the Novartis sponsored trials in which OA was studied in the UK and is also involved in clinical trials sponsored by Biogen, Roche and Dyne. She has received consulting fees from Roche, Biogen and Novartis. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}